Implications of the metabolic syndrome: The new epidemic

American Journal of Cardiology

Volumn 96, Issue 4 SUPPL., 2005, Pages 3-7

  Sorrentino, Matthew J ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b MC 6080 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; VALSARTAN;

ABDOMINAL AORTA ANEURYSM; AEROBIC METABOLISM; AGE DISTRIBUTION; ARTERY DISEASE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC OBESITY; DYNAMIC EXERCISE; DYSLIPIDEMIA; ELECTRON BEAM TOMOGRAPHY; EPIDEMIC; FAMILY HISTORY; GLUCOSE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE; METABOLIC SYNDROME X; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; SCREENING TEST; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 23744468393     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.05.008     Document Type: Conference Paper

References (20)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 258 2001 2486 2497
2. R.B. D'Agostino, S. Grundy, L.M. Sullivan, P. Wilson CHD Risk Prediction Group Validation of the Framingham coronary heart disease prediction scores JAMA 286 2001 180 187
3. J. Liu, Y. Hong, R.B. D'Agostino, Z. Wu, W. Wang, J. Sun, P.W.F. Wilson, W.B. Kannel, D. Zhao Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese multi-provincial cohort study JAMA 291 2004 2591 2599
4. M.J. Sorrentino, L. Pham, T. Nguyen Inflammation and vascular disease the role of C-reactive protein J Geriatr Cardiol 1 2004 17 20
5. M.A. Albert, R.J. Glynn, P.M. Ridker Plasma concentration of C-reactive protein and the calculated Framingham coronary heart disease risk score Circulation 108 2003 161 165
6. W. Koening, H. Lowel, J. Baumert, C. Meisinger C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment. Results from a large cohort study in Southern Germany Circulation 109 2004 1349 1353
7. P.M. Ridker, J.E. Buring, N.R. Cook, N. Rifai C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events Circulation 107 2003 391 397
8. P.M. Ridker, P.W.F. Wilson, S.M. Grundy Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 109 2004 2818 2825
9. Y.-W. Park, S. Zhu, L. Palaniappan, S. Heshka, M.R. Carnethon, S.B. Heymsfield The metabolic syndrome prevalence and associated risk factor findings in the US population from the third National Health and Nutrition Examination Survey, 1988-1994 Arch Intern Med 163 2003 427 436
10. D.S. Freedman, L.K. Khan, M.K. Serdula, D.A. Galuska, W.H. Dietz Trends and correlates of class 3 obesity in the United States from 1990 through 2000 JAMA 288 2002 1758 1761
11. J.E. Manson, W.C. Willett, M.J. Stampfer, G.A. Colditz, D.J. Hunter, S.E. Hankinson, C.H. Hennekens, F.E. Speizer Body weight and mortality among women N Engl J Med 333 1995 677 685
12. P.T. Katzmarzyk, T.S. Church, S.N. Blair Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men Arch Intern Med 164 2004 1092 1097
13. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
14. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals a randomised placebo-controlled trial Lancet 360 2002 7 22
15. H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A.W. Neil, S.J. Livingstone, M.J. Thomason, M.I. Mackness, V. Charlton-Menys, J.H. Fuller CARDS investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
16. P.S. Sever, B. Dahlof, N.R. Poulter, H. Wedel, G. Beevers, M. Caulfield, R. Collins, S.E. Kjeldsen, A. Kristinsson, G.T. McInnes ASCOT investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) a multicentre randomised controlled trial Lancet 361 2003 1149 1158
17. H.B. Rubins, S.J. Robins, D. Collins, C.L. Fye, J.W. Anderson, M.B. Elam, F.H. Faas, E. Linares, E.J. Schaefer, G. Schectman Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N Engl J Med 341 1999 410 418
18. V. Manninen, L. Tenkanen, P. Koskinen, J.K. Huttunen, M. Manttari, O.P. Heinonen, M.H. Frick Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol on coronary heart disease risk in the Helsinki Heart Study Circulation 85 1992 37 45
19. E. Chiquette, G. Ramirez, R. DeFronzo A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors Arch Intern Med 164 2004 2097 2104
20. S. Julius, S.E. Kjeldsen, M. Weber, H.R. Brunner, S. Ekman, L. Hansson, T. Hua, J. Laragh, G.T. McInnes, L. Mitchell VALUE Trial Group Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine the VALUE randomised trial Lancet 363 2004 2022 2031